Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.
Melanoma (Skin)
BIOLOGICAL: dendritic cell-MART-1 peptide vaccine
Optimal dose, 7 months
Safety of administering MART-1 adenovirus transduced dendritic cells, 7 months|Immunological response (peptide-specific T cell generation, skin test immunohistology), 7 months|Clinical response (disease improvement or disease progression), 7 months
RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.